National Acalabrutinib Observational Study - NAOS

Study identifier:D8220R00045

ClinicalTrials.gov identifier:NCT05437250

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A French multicentric observational study of acalabrutinib in the treatment of Chronic Lymphocytic Leukemia patients

Medical condition

Chronic Lymphocytic Leukemia

Phase

N/A

Healthy volunteers

No

Study drug

Non interventional study

Sex

All

Actual Enrollment

350

Study type

Observational

Age

18 Years - n/a

Date

Study Start Date: 13 Sept 2022
Estimated Primary Completion Date: 15 Nov 2026
Estimated Study Completion Date: 15 Nov 2026

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria